- Home
- CHNR vs CVKD Comparison
CHNR vs CVKD Comparison
Compare CHNR & CVKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CHNR | CVKD |
|---|---|---|
| Founded | N/A | 2022 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Medicinal Chemicals and Botanical Products |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.1M | 20.7M |
| IPO Year | 1995 | 2023 |
Fundamental Metrics
Financial Performance| Metric | CHNR | CVKD |
|---|---|---|
| Price | $3.49 | $6.87 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $32.00 |
| AVG Volume (30 Days) | 15.8K | ★ 79.8K |
| Earning Date | 12-31-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.16 | $6.42 |
| 52 Week High | $8.20 | $22.90 |
Technical Indicators
Market Signals| Indicator | CHNR | CVKD |
|---|---|---|
| Relative Strength Index (RSI) | 39.90 | 37.73 |
| Support Level | $3.43 | $6.42 |
| Resistance Level | $3.82 | $7.58 |
| Average True Range (ATR) | 0.17 | 0.79 |
| MACD | -0.01 | 0.01 |
| Stochastic Oscillator | 15.12 | 19.87 |
Price Performance
Historical ComparisonAbout CHNR China Natural Resources Inc.
China Natural Resources Inc is engaged in exploration for lead, silver, and other metals in the Inner Mongolia Autonomous Region of the PRC and exploration of attractive opportunities in other sectors. The company has a single operating segment: exploration and mining.
About CVKD Cadrenal Therapeutics Inc.
Cadrenal Therapeutics Inc is developing tecarfarin, its drug candidate, for unmet needs in anticoagulation therapy. Tecarfarin is a late-stage novel oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation.